Helius Medical Technologies, Inc. Announces Successful Warrant Exercise
Helius Medical Technologies, Inc. (Nasdaq:HSDT), a pioneer in neurotechnology dedicated to improving the lives of individuals with neurological conditions, has recently made an exciting announcement. The company has successfully entered into agreements to exercise existing warrants for 4,971,110 shares of its common stock. This strategic move, priced at a reduced exercise rate of $0.751 per share, is expected to generate approximately $3.7 million in gross proceeds before deducting financial advisory fees. The funds are poised to reinforce Helius’ mission of advancing innovative therapeutic solutions.
Strategic Financial Advisory and Shareholder Involvement
As part of this transaction, Roth Capital Partners has been appointed as the financial advisor, showcasing the commitment of Helius Medical Technologies to ensure a successful funding strategy. Crucially, the exercise of the new warrants and the issuance of shares are contingent upon shareholder approval, a necessary step as dictated by Nasdaq regulations. This reflects the company’s transparency and adherence to proper governance protocols in managing financial activities.
Details on New Warrants and Stockholder Approval
The holders exercising the existing warrants will be issued new warrants to purchase up to 6,213,888 shares of common stock, reinforcing investor confidence in Helius. However, the actual exercisability of these new warrants still hinges on obtaining the necessary stockholder approval.
Overview of the Portable Neuromodulation Stimulator
At the heart of Helius Medical Technologies’ offerings is the Portable Neuromodulation Stimulator (PoNS). This innovative device represents a breakthrough in non-invasive neuromodulation therapy, designed to aid those suffering from balance and gait deficits. The PoNS device works by delivering neurostimulation via a mouthpiece connected to a controller. Its primary use is in conjunction with physical rehabilitation exercises, and it has been specifically indicated for short-term treatment related to multiple sclerosis (MS) symptoms.
Proven Efficacy in Clinical Applications
In addition to its application in MS, the PoNS device has demonstrated effectiveness in treating stroke patients, enhancing gait and balance, and significantly reducing fall risks. The device has received authorization for various uses, including treatment for the effects of mild to moderate traumatic brain injury and supporting physical therapy initiatives. In Canada, it has been recognized for its efficacy through distinct authorizations for three different therapeutic indications.
Advancements in Neurotechnology and Future Directions
Helius Medical Technologies continues to be at the forefront of neurotechnology, with a commitment to enhancing neuroplasticity and physiologic compensatory mechanisms. Its innovative solutions are pivotal for individuals facing neurological challenges, and the company’s ongoing dedication to research and development is integral to its growth strategy. The introduction of the PoNS device represents a significant leap in therapeutic options available to patients.
Company Background and Contact Information
Founded with the aim of addressing neurologic deficits, Helius Medical Technologies employs an orally applied technology platform that significantly amplifies brain functionality. Their vision underlines the importance of addressing crucial health challenges faced by many people today. For those interested in learning more about Helius and the PoNS therapy, additional information can be found on their official website.
Frequently Asked Questions
What is the purpose of the recent warrants exercise by Helius Medical Technologies?
The warrants exercise is intended to raise approximately $3.7 million to support the company's development and innovation in neurotechnology solutions.
How does the Portable Neuromodulation Stimulator (PoNS) work?
PoNS delivers neurostimulation through a mouthpiece and works in conjunction with physical rehabilitation exercises to improve balance and gait.
Is shareholder approval required for the new warrants and shares?
Yes, the exercisability of the new warrants and issuance of shares is contingent upon obtaining shareholder approval in line with Nasdaq regulations.
In which regions is the PoNS device available for clinical use?
PoNS has received authorization for use in the United States, Canada, and Australia, targeting various neurological conditions.
Who can I contact for more information regarding Helius Medical Technologies?
For inquiries, individuals can contact Philip Trip Taylor at Gilmartin Group via the provided email for investor relations.
